早产儿呼吸窘迫综合征与ARDS拔管后经鼻高频振荡通气:一项随机对照试验
该单中心随机对照试验纳入206例胎龄<37周、准备拔管的机械通气早产儿,随机分为NHFOV组与NCPAP组。主要结局为1周内再插管率和6小时内Pco2水平。NHFOV组再插管率显著低于NCPAP组(16:87 vs 35:68,95%CI 0.18-0.70,P=0.002),尤其在胎龄≤32周亚组(12:34 vs 25:20,95%CI 0.12-0.68,P=0.004)及ARDS亚组(10:33 vs 21:15,95%CI 0.08-0.57,P=0.002)。NHFOV组Pco2水平亦显著降低(49.6±8.7 vs 56.9±9.9,95%CI -9.95至-4.80,P<0.001)。作者认为NHFOV在避免再插管方面优于NCPAP,尤其在极早产儿和ARDS患儿中。
要点
- 拔管后NHFOV较NCPAP显著降低早产儿1周内再插管率(16:87 vs 35:68,P=0.002)。
- 胎龄≤32周亚组中NHFOV再插管率显著低于NCPAP(12:34 vs 25:20,P=0.004)。
- ARDS亚组中NHFOV再插管率显著低于NCPAP(10:33 vs 21:15,P=0.002)。
- NHFOV组6小时内Pco2显著低于NCPAP组(49.6±8.7 vs 56.9±9.9,P<0.001)。
- 作者认为NHFOV在避免再插管方面优于NCPAP,尤其适用于极早产儿和ARDS患儿。
适用人群与场景
- 胎龄<37周、准备拔管的机械通气早产儿,随机分为NHFOV组或NCPAP组。
研究设计与关键结果
- 单中心随机对照试验,纳入206例早产儿;127例(61.7%)诊断为呼吸窘迫综合征,53例(25.7%)诊断为ARDS,26例(12.6%)同时诊断为呼吸窘迫综合征和ARDS。
- NHFOV组与NCPAP组1周内再插管率分别为16:87与35:68,NHFOV显著降低再插管率(95%CI 0.18-0.70,P=0.002)。
- 胎龄≤32周亚组中,NHFOV组与NCPAP组再插管率分别为12:34与25:20,NHFOV显著降低(95%CI 0.12-0.68,P=0.004)。
- ARDS亚组中,NHFOV组与NCPAP组再插管率分别为10:33与21:15,NHFOV显著降低(95%CI 0.08-0.57,P=0.002)。
- 6小时内Pco2水平NHFOV组为49.6±8.7,NCPAP组为56.9±9.9,NHFOV组显著降低(95%CI -9.95至-4.80,P<0.001)。
证据类型、等级与局限
- 随机对照试验;注册号ClinicalTrials.gov NCT03140891;研究于2017年5月至2018年5月进行。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为NHFOV在避免再插管方面优于NCPAP,尤其适用于极早产儿和ARDS患儿。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Nasal high-frequency oscillatory ventilation (NHFOV) has been described as supplying the combined advantages of nasal CPAP (NCPAP) and HFOV. However, its effect on preterm infants needs to be further elucidated. Our objective was to assess whether NHFOV could reduce intubation and Pco2 levels as compared with NCPAP during the postextubation phase in preterm infants.
METHODS: This was a single-center, randomized, controlled trial, and it was registered at clinicaltrials.gov (NCT03140891) and conducted between May 2017 and May 2018. Ventilated infants born at less than 37 weeks' gestational age and ready to be extubated were included and randomized to either the NHFOV or NCPAP group. Primary outcomes were the incidence of reintubation within 1 week and the Pco2 level within 6 h.
RESULTS: A total of 206 preterm infants were included. Of them, 127 (61.7%) were diagnosed with respiratory distress syndrome, 53 (25.7%) with ARDS, and 26 (12.6%) with both respiratory distress syndrome and ARDS. Comparing with NCPAP, NHFOV significantly reduced the reintubation rate (16:87 vs 35:68; 95% CI, 0.18-0.70; P = .002), especially in the subgroup with a gestational age of ≤ 32 weeks (12:34 vs 25:20; 95% CI, 0.12-0.68; P = .004). The Pco2 level was also significant lower in the NHFOV group (49.6 ± 8.7 vs 56.9 ± 9.9; 95% CI, -9.95 to -4.80; P = < .001). Moreover, NHFOV significantly reduced the reintubation rate in preterm infants with ARDS (10:33 vs 21:15; 95% CI, 0.08-0.57; P = .002).
CONCLUSIONS: NHFOV was shown to be superior to NCPAP in avoiding reintubation, especially in very preterm infants and those infants diagnosed with ARDS.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03140891; URL: www.clinicaltrials.gov.
参考来源
- Chen L, Wang L, Ma J, et al. Nasal High-Frequency Oscillatory Ventilation in Preterm Infants With Respiratory Distress Syndrome and ARDS After Extubation: A Randomized Controlled Trial. Chest. 2019. PMID: 30955572. doi:10.1016/j.chest.2019.01.014
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。